Eton Pharmaceuticals, Inc. (ETON) 8-K Current Report: March 2, 2026
Filed: March 2, 2026
Health Care
Pharmaceutical PreparationsEton Pharmaceuticals, Inc. (ETON) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 1.01: Entry into a Material Definitive Agreement
Eton Pharmaceuticals, Inc. 8-K Mar 2, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • $14.0M upfront + 8% royalty on net sales for patent life; ~$2.2M additional inventory purchases at closing and May 2026
- • Financed entirely from cash on hand; deal expected accretive to 2026 earnings
- • HEMANGEOL 2025 net sales ~$11.7M per IQVIA — implies deal valued at ~1.2x trailing revenue
- • Orphan Drug designation for infantile hemangioma provides competitive moat and potential pricing power
- • Pierre Fabre continues U.S. distribution through April 30, 2026, reducing near-term commercial execution risk for Eton
Other Eton Pharmaceuticals, Inc. 8-K Filings
Get deeper insights on Eton Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.